Solid Tumor Testing in China Trends and Forecast
The future of the solid tumor testing market in China looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets. The global solid tumor testing market is expected to reach an estimated $1641.7 billion by 2031 with a CAGR of 3.5% from 2025 to 2031. The solid tumor testing market in China is also forecasted to witness strong growth over the forecast period. The major drivers for this market are an increase in the utilization of supplements and steroids and an increase in unhealthy habits, such as smoking and alcohol consumption.
• Lucintel forecasts that, within the application category, melanoma is expected to witness the highest growth over the forecast period due to the growing incidence of skin tumors and related conditions globally.
• Within the end use category, the hospital is expected to witness the highest growth due to the rising incidence of tumors and chronic diseases.
Emerging Trends in the Solid Tumor Testing Market in China
The market for solid tumor testing in China is rapidly changing due to technological advances, regulatory shifts, and increased funding in the healthcare sector. As the nation works to enhance cancer diagnosis and treatment, innovations targeting different testing methods have increased significantly. New liquid biopsy approaches, AI for diagnostics, precision medicine, genetic profiling, and systematic national screening programs are some of the trends that define this rapidly changing environment. These developments are paving the way for more precise and efficient solid tumor testing in China.
• Liquid Biopsy Technologies Adoption: One of the significant trends to watch within China’s solid tumor testing market is liquid biopsies. This non-invasive technique, which captures the presence of cancerous tumor-derived DNA from blood samples, is gaining traction as a go-to diagnostic method. Liquid biopsies speed up the diagnosis of cancer owing to their non-invasive features, minimal hindrance, and quick results. With the growing emphasis on cancer progression detection in real-time, liquid biopsy stands to assume prominence in cancer management in China, improving patient outcomes while simultaneously reducing the burden on healthcare services through better resource allocation.
• The Role of Artificial Intelligence (AI) in Diagnostics: The effective use of solid tumor testing in China is greatly aided by AI-driven imaging systems. AI imaging systems integrated into CT scans and MRIs significantly improve the chances of detecting minute tumor changes that would otherwise go undetected. This technology enables doctors to provide timely and accurate diagnoses, which leads to more effective treatment plans. The potential uses of AI technology are seemingly endless. By integrating AI systems into healthcare, the speed and affordability of testing can greatly improve, which would reduce the chances of irreversible human error. The integration of AI technology will provide a more holistic approach to the human element behind it.
• Targeted Therapies and Personalized Medicine: The utilization of genetic profiling for solid tumor testing has enabled personalized medicine to expand in China, which is a positive sign for the healthcare industry. The analysis of a tumor’s genetic makeup allows a doctor to determine tailored therapies with more effective outcomes and fewer adverse reactions. This progression toward precision oncology will make even the most difficult cancers easier to treat. As the field of personalized medicine progresses, the solid tumor testing industry in China is expected to greatly benefit from the rise in targeted therapies, which in turn will improve survival chances and quality of life for patients suffering from cancer.
• Genomic Profiling for Early Detection and Monitoring: In China, genomic profiling is emerging as an important part of the process of solid tumor testing. It enables the sequencing of tumors where mutations and alterations that best define the treatment options are recognized. Genomic profiling also assists in the diagnosis of cancer and in tracking the progression, as well as resistance to treatment. This development is making early detection possible and allowing clinicians to intervene earlier, thus fundamentally improving the survival rates and prognosis for patients suffering from solid tumors.
• Expansion of National Cancer Screening Programs: China is markedly increasing its national initiatives for cancer screening, especially for lung, breast, and colorectal cancer. These initiatives aim to detect malignant cells at an earlier stage so that treatment can be more effective, resulting in decreased mortality rates. The solid tumor testing market is experiencing a surge in the need for diagnostic services as a result of the government’s intention to boost screening efforts. This trend encourages earlier interventions, decreases long-term treatment expenditures, and improves the general public’s knowledge about cancer prevention and early diagnosis.
The growth of the China solid tumor testing market is highly active due to the adoption of technologies such as liquid biopsy, AI, genetic mapping, and personalized medicine, along with national screening programs. These trends are changing the landscape of cancer diagnosis and treatment in ways that are both more precise and effective than before. If these trends are sustained, China will witness significant improvements in managing cancer, and patient experiences will also improve.
Recent Developments in the Solid Tumor Testing Market in China
The last few years have witnessed rapid expansion in China’s solid tumor testing market due to high technological development, regulatory changes, and new investments in healthcare. New initiatives have been introduced by the government and healthcare system focusing on cancer diagnosis research and treatment for solid tumors as well as efforts to improve the overall processes. Liquid biopsy, imaging AI, personalized medicine, genomic profiling, and national screening programs are among the more significant recent solid tumor testing innovations. These developments are part of a much-needed new strategy in cancer detection that is fast, cost-effective, and accurate.
• Rise of Liquid Biopsy Technologies: Liquid biopsy technologies are emerging as a major trend within China’s market for solid tumor testing. This test provides a non-invasive method of capturing circulating tumor DNA (ctDNA) from blood, which facilitates prompt diagnosis and progression monitoring. Liquid biopsies have become increasingly popular as they can capture tumors and other cancerous growths at more advanced stages, reducing the need for surgical intervention. This technology will play an important role in China’s battle against cancer as it becomes more available and economical.
• Artificial Intelligence in Imaging and Diagnostics: The use of artificial intelligence technology in diagnostic imaging is an important advancement in China’s market for solid tumor testing. Specialized software is used to automatically analyze CT, MRI, and X-ray studies, allowing radiologists to spend less time on interpretation while increasing the accuracy of the diagnosis at the same time. These AI systems recognize even minute changes in the size or form of the tumor, allowing more precise diagnosis and better planning of therapeutic measures. China’s solid tumor testing market would greatly benefit from enhanced AI, which is an extremely accurate diagnosis tool with little room for human error.
• The Expansion of Personalized Medicine: In China, personalized medicine is on the cutting edge of innovation, as China is one of the pioneers in medicine focused on a patient’s phenotype. With the aid of genomic profiling, physicians can develop newer and more effective therapies that include fewer dangerous side effects. This advancement is particularly important in the context of treating solid tumors since it uses more precise and individualized care. It is clear that as the market and supply of personalized medicine expands, the availability of genetic testing and tumor profiling will grow, which will consequently stimulate further development and innovation in the solid tumor testing market.
• The Progress of Genomic Profiling Innovations: The development of genomic profiling technology is a core improvement in China’s solid tumor testing market. It aids physicians in sequencing DNA from tumor cells and pinpointing mutations and variations that may be helpful in determining treatment options. In addition, genomic profiling is useful in monitoring newly diagnosed cancer patients because it is key to developing treatment plans, tracking the progress of the disease, and determining how aggressive it is. This advancement is promising because the development and adoption of more sophisticated and inexpensive genomic profiling tools will improve the precision and accuracy of solid tumor diagnosis and treatment, saving the lives of many patients.
• Expansion of National Cancer Screening Programs: China is scaling up national cancer screening programs in order to enhance the detection of solid tumors, especially in lung, breast, and colorectal cancer. These programs are designed to capture cancer at its most manageable stages. The government has pledged to boost overall screening rates, which is anticipated to stimulate the need for diagnostic testing services throughout the country. These measures not only support early detection but also call for enhanced cancer control and awareness, which will lower the mortality rates from cancer in China.
The recent changes in the growth of the solid tumor testing market in China focus on sophisticated methods like liquid biopsy, AI, genomic profiling, and personalized medicine. Together with the expansion of national screening programs, these technologies are changing the paradigm of cancer diagnosis and treatment. These changes will ensure timely diagnosis, reduce the cancer burden, and relieve patient suffering with well-tailored and effective treatment. As these changes unfold, they will transform cancer treatment in China to achieve improved health results for patients and greater efficiency in the health system.
Strategic Growth Opportunities for Solid Tumor Testing Market in China
The market for China’s solid tumor testing is developing at an unprecedented rate due to increasing healthcare expenditure, the rise in cancer cases, the improvement in government health services, and greater technological accessibility. The use of liquid biopsy, genomic sequencing, and Artificial Intelligence-powered diagnostics significantly broadens the scope for the market expansion of solid tumors. This development is not only elevating the healthcare industry but also making great strides toward the early identification, treatment, and control of solid tumors, resulting in better healthcare outcomes and reduced expenditures in China.
• Liquid Biopsy Innovation as a Primary Method for Early Cancer Identification: In China, blood sample tests that detect Circulating Tumor DNA (ctDNA) are a promising opportunity for expanding the solid tumor testing market. The non-invasive method serves a purpose in cancer screening, but more importantly, the technology is extremely powerful in real-time cancer progression monitoring, which greatly impacts treatment plans. As China advances toward better cancer diagnostic measures, liquid biopsy genomic sequencing will increase efficiency within clinical environments by alleviating treatment waiting times, thus improving patient outcomes and working with healthcare budgets more effectively.
• AI-Powered Diagnostics for Greater Accuracy: In China, the testing and diagnosis of solid tumors based on AI is actively changing the landscape of China’s malign solid tumor testing industry. The presence of AI in imaging systems, for example, CT scans and MRIs, allows for much earlier and more precise identification of small tumor changes. AI’s data analysis capabilities are diagnosing tumors with accuracy that was never possible before. By making it easier to detect tumors accurately, AI reduces the chances for human errors and assists in more timely and efficient treatment, therefore making positive impacts on Chinese healthcare.
• Genomic Profiling Increases the Need for Precision Medicine: Advances in genomics have made it possible to tailor therapies based on specific genetic mutations found within particular tumors to increase the chances of successful treatment. As more precise medicine is practiced in China, the demand for genomics is likely to grow. This system organizes treatment procedures in a manner where the negative impact of the treatment is minimized, while the effectiveness of the treatment is maximized. As cancer treatment shifts toward a more personalized method, genomic profiling will have to increase, resulting in further growth in the solid tumor testing industry to ensure effective care is administered to patients.
• Enhancement of Cancer Screening at the National Level: China’s government is improving national screening programs, which include lung, breast, and colorectal cancers. The programs are set up to identify cancer at the earliest possible stage for treatment to maximize survival rates. This expansion presents an opportunity for growth in solid tumor testing because increased screenings will improve the demand for diagnostic testing products. Finding more cancer cases earlier will also increase the demand for advanced testing technologies like liquid biopsies and AI diagnostics, which sets up the scope for market enhancement.
• Modern Health Technology Adoption: The adoption of modern health technologies, including remote patient observation and telemedicine, combined with solid tumor testing, creates tremendous potential for growth. It allows better management of patient information, improved interaction between healthcare professionals, and easier access to diagnostic tests. Technology from the digital health industry will streamline the process of cancer diagnosis and monitoring, making it possible to broaden the geography of cancer testing services even in the remote parts of China. This will foster effective cancer detection in underserved regions.
The solid tumor testing market in China is experiencing strategic growth in areas such as liquid biopsy, AI diagnostics, customized medicine, national health screening, and digital health. These opportunities are transforming cancer diagnosis and therapy precision, early diagnosis, and patient outcomes. These technologies will further advance the cancer care market in China, improving the efficiency of service delivery and overall outcomes in cancer control in the country.
Solid Tumor Testing Market in China Driver and Challenges
A blend of technology, economics, and legal frameworks shapes the solid tumor testing market in China. These factors and issues are particularly important in the context of cancer diagnosis and treatment in the country. The increasing global burden of cancer is driving the creation of new markets, but these markets also bring new challenges. The knowledge of both the driving forces and the barriers will help stakeholders strategize their market approach and achieve desired growth while overcoming obstacles.
The factors responsible for driving the solid tumor testing market in China include:
• The Development of New and Sophisticated Diagnostic Products: The solid tumor testing market in China is likely to flourish immensely because of cutting-edge diagnostic technologies such as AI imaging, liquid biopsy, and genomic analysis/profiling. These technologies foster more precise and effective tumor identification, making it possible to diagnose cancer more accurately. The efforts are expected to improve outcomes for patients by offering more advanced treatment plans and better observation of tumor changes, which will enhance growth in the solid tumor testing market.
• Government Support and Cancer Screening Programs: China has benefitted greatly from government-funded programs directed at the prevention of cancer and its early detection. These initiatives primarily concern the expansion of existing national cancer screening programs, the goal of which is to increase the chances of cancer treatment by identifying it early. There is growing funding as well as supportive regulations for cancer research and diagnostics, which are fueling growth in the solid tumor testing market. The diagnostic tests market has sharply increased as the government provides screening, and subsequently the technology for these tests.
• Increasing Cases of Cancer and the Self-Sufficient Technological Market: With the rise in China’s elderly population and the increasing cases of cancer, there is a heightened need for solid tumor testing. In addition, the increase in lung, breast, and colorectal cancer cases has set the expectation of more accurate results being diagnosed. This particular demographic is increasing the market need because early detection is key to increasing life expectancy and decreasing the overall health burden. Due to the public understanding of the severity of cancer risks, there will be a greater need for advanced testing technologies, therefore increasing sales further.
• Increased Investment in the Precision Medicine Sector: Unlike broad oncology, precision oncology focuses on solid tumor treatment by analyzing the patient’s DNA. With the rise of genomic analysis along with specific therapies offered in China, there is a more prominent need for solid tumors to be tested for particular mutations or genetic changes. Like all trends, precision oncology is increasing the need for solid tumor testing technologies, therefore expanding the market. Adoption of precision medicine is very helpful in attaining desirable results, especially in avoiding unwanted side effects.
• Collaboration and Partnerships in the Healthcare Ecosystem: The development and implementation of sophisticated testing technologies in China is benefiting from strategic cooperation between healthcare providers, research institutions, and technology corporations. These partnerships enable the sharing of expertise, resources, and data, which accelerates innovation and the deployment of new technologies. With the increasing importance of partnerships, the solid tumor testing market is improving through multifaceted investments, rapid technology deployment, and the incorporation of new technologies into clinical practice.
Challenges in the solid tumor testing market in China are:
• High Costs of Advanced Diagnostic Technologies: The advanced methods employed in solid tumor testing may expand the market; however, the high price of advanced technologies challenges growth. The newest diagnostic tools, including AI-based imaging systems and liquid biopsies, are exceptionally costly to develop and implement. Test accessibility, especially in low-income regions, is a main issue, particularly for uninsured patients. To fully integrate these technologies into a healthcare system, the pricing issue must first be addressed.
• Delays in the Market Process and Approval: As with other types of medical technology, the approval and acceptance of new technologies in China takes a long time. The approval delays of sophisticated diagnostic tools and testing methods impede the market from expanding as well as limit the supply of new and effective cutting-edge solutions. Even though China has made some strides in improving regulatory processes, the pace of approval for new solid tumor testing automation technologies is still very sluggish. Through collaboration and understanding the importance of bringing new innovations to market, companies need to ensure that regulators ease the approval burden.
• Scarcity of Advanced Medical Practitioners: Even with existing technological challenges, there are still too few advanced solid tumor testing technologies-trained personnel to meet the expectations of the models. Training in genomic profiling, liquid biopsy approaches, and AI-based diagnostic systems needs to be enhanced to ensure maximum effectiveness of these tools. Solid tumor tests can only be truly effective if there is an adequate number of skilled personnel to apply the new technological approaches of interpreting and utilizing these advanced technologies. Education and training programs need to be implemented to mitigate this undersupply issue to ensure the successful use of advanced techniques in day-to-day clinical practice.
The solid tumor testing market segment in China is expanding due to the growth of technology, government initiatives, increasing cancer cases, and the movement toward advanced medicine. Even so, market growth is restrained by factors such as high expenditure, latency in regulatory processes, and a lack of trained manpower for modern diagnostic technologies. Solving these problems will be crucial for realizing the full potential of the market and broadening access to sophisticated diagnostic devices in places where they are most needed. China stands to benefit significantly from further development in this area, as it presents a substantial opportunity to improve cancer detection and treatment outcomes in the country.
List of Solid Tumor Testing Market in China Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, solid tumor testing companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the solid tumor testing companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10
Solid Tumor Testing Market in China by Segment
The study includes a forecast for the solid tumor testing market in China by type, application, and end use.
Solid Tumor Testing Market in China by Type [Analysis by Value from 2019 to 2031]:
• Genetic Testing
• Conventional Testing
Solid Tumor Testing Market in China by Application [Analysis by Value from 2019 to 2031]:
• Prostate
• Breast
• Colorectal
• Endometrial
• Lung
• Melanoma
• Others
Solid Tumor Testing Market in China by End Use [Analysis by Value from 2019 to 2031]:
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutions
Features of the Solid Tumor Testing Market in China
Market Size Estimates: Solid tumor testing in China market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Solid tumor testing in China market size by type, application, and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different type, application, and end use for the solid tumor testing in China.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the solid tumor testing in China.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What are the major drivers influencing the growth of the solid tumor testing market in China?
Answer: The major drivers for this market are increase in the utilization of supplements and steroids and increase in unhealthy habits, such as smoking and alcohol consumption.
Q2. What are the major segments for solid tumor testing market in China?
Answer: The future of the solid tumor testing market in China looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets.
Q3. Which solid tumor testing market segment in China will be the largest in future?
Answer: Lucintel forecasts that melanoma is expected to witness the highest growth over the forecast period due to growing incidence of skin tumors and related conditions globally.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 10 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the solid tumor testing market in China by type (genetic testing and conventional testing), application (prostate, breast, colorectal, endometrial, lung, melanoma, and others), and end use (hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Solid Tumor Testing Market in China, Solid Tumor Testing Market in China Size, Solid Tumor Testing Market in China Growth, Solid Tumor Testing Market in China Analysis, Solid Tumor Testing Market in China Report, Solid Tumor Testing Market in China Share, Solid Tumor Testing Market in China Trends, Solid Tumor Testing Market in China Forecast, Solid Tumor Testing Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.